New COVID-19 Saliva Test Makes Testing Far Easier for All Ages
14.7.2021 10:00:00 EEST | Business Wire | Press release
UK company Intelligent Fingerprinting, manufacturers of the world’s first and only fingerprint sweat drug test, has now developed an easy-to-use saliva-based lateral flow test for the rapid detection of the COVID-19 antigen. In contrast to existing COVID-19 tests that require unpleasant, invasive nose and throat swabs, Intelligent Fingerprinting’s test uses a simple swab to collect a saliva sample just from the inside of the cheek. The test strip is deliberately simple in design and engineered to keep plastic usage to a minimum - with none of the plastic casing present that is usually associated with lateral flow tests.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005243/en/
New COVID-19 saliva test makes testing far easier for all ages. How it works: A swab is used to collect the saliva sample from the inside of the lower cheek, which is then mixed with a reagent buffer that has been pre-added to the collection tube in order to release the virus. The screening test is performed by inserting the tip of the VSS-GP test strip into the sample, providing a positive or negative result at 20 minutes. No instrumentation is required. The test uses gold immunonanoparticle technology to enable the visual detection of bound antigen via a control line and a red line on the test strip when a saliva sample is positive for the SARS-CoV-2 antigen. (Photo: Business Wire)
The Intelligent Fingerprinting COVID-19 test’s easy saliva sample collection makes it particularly suitable for testing more vulnerable people and children. It facilitates frequent testing across a range of applications including schools, workplaces, public events, care homes, healthcare, airports and prisons. Test results are available in 20 minutes – a third quicker than most current nose and throat lateral flow tests.
“Almost everyone who has taken a nose or throat swab to test for COVID-19 knows just how unpleasant they can be. In developing our new COVID-19 saliva test, we have successfully combined the benefits of much simpler sample collection with high levels of accuracy using our existing technology,” explained Intelligent Fingerprinting’s Executive Chairman Philip Hand.
“The introduction of our new COVID-19 test involved rapid design, development and manufacture within the UK over a ten-month period. Manufacturing capacity at our Cambridge plant, utilising existing equipment and ISO 13485 quality control, is ready to support the production of millions of tests per month, and we also anticipate we will be working with existing and new distribution partners to make this test available across multiple markets,” he added.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005243/en/
Contact information
cheryl.billson@commacomms.com
+44(0)7791 720460
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Reports Third Quarter 2026 Results3.11.2026 23:30:00 EET | Press release
IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2026. Results are presented on a continuing operations basis, excluding the Food Ingredients business and other minor perimeter adjustments (the “Food Ingredients disposal group”), and the Soy Crush, Concentrates, and Lecithin businesses (the “SCL disposal group”). The Food Ingredients disposal group and the SCL disposal group are reported as discontinued operations. Management Commentary “IFF delivered a solid third quarter, with improved sales and profitability across all divisions,” said Erik Fyrwald, CEO of IFF. “Taste and Scent delivered strong top- and bottom-line results, and Health & Biosciences improved modestly as we continue to strengthen the business. We also generated strong cash flow through the first nine months of 2026 and recently completed our $500 million accelerated share repurchase program. The separation of Food Ingredients is progressing well, and we are on track with our timelin
2026–2027 World Branding Awards Honours Global “ Brand of the Year ” Winners at Hampton Court Palace3.11.2026 22:00:00 EET | Press release
The World Branding Awards returned to honour the brands that continue to set the benchmark for excellence. The 2026–2027 World Branding Awards Ceremony took place at the iconic Hampton Court Palace, marking the 21st edition of the awards. Set within the grandeur of a historic venue, the prestigious event brought together guests from across the globe for a memorable celebration. The evening was hosted by the acclaimed BBC presenter, Hannah Gray, and was further enriched by a keynote presentation from renowned speaker Adrian Webster. Earning a World Branding Awards remains a highly distinguished achievement. Winners are determined through a rigorous evaluation process encompassing brand valuation, consumer market research, and public online voting. This year, over 105,000 consumers took part in the voting process, and more than 2,000 brands from 62 countries were nominated. Of these, less than 10 brands from each country were declared the “Brand of the Year” across the Global, Regional,
Gencom Acquires Rosewood London, Expanding Its Footprint With Its First Luxury Hotel Acquisition in Europe3.11.2026 20:05:00 EET | Press release
Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London, the landmark 308-key luxury hotel situated at 252 High Holborn in Central London. The acquisition strengthens Gencom’s global hospitality investment platform and expands its presence in Europe through its first luxury hotel asset in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103137897/en/ Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London in Central London London is one of the world’s most supply-constrained hospitality markets, supported by year-round demand from both leisure and business travelers. The acquisition of Rosewood London reflects Gencom’s conviction in the market and serves as a strategic entry point into Europe. The transaction further enhances the firm’s assemblage
SGCA Honours Communication Excellence Across Asia, Europe and the Arab World3.11.2026 17:52:00 EET | Press release
His Highness Sheikh Dr Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, honoured winners of the 13th Sharjah Government Communication Award (SGCA), organised by the Sharjah Government Media Bureau (SGMB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103972039/en/ SGCA honours communication excellence across Asia, Europe and the Arab world (Photo: AETOSWire) Winners represented China, India, Thailand, Ukraine and the Arab world. Some 433 entries from 31 countries across four continents passed initial screening. The award covered 23 categories across five sectors, including six partner awards. His Excellency Tariq Saeed Allay, Director General of SGMB, highlighted the award’s growth under the vision of His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, noting that it had attracted more than 9,500 entries over five year
BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 17:03:00 EET | Press release
BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inventor Dr. Farid Bennis, the technology uses a dissolvable effervescent tablet to create a buffered solution that helps protect peptides during gastrointe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom